Novartis sues Medimmune, Biogen and Alexion


Novartis sues Medimmune (subsidiary of astrazeneca), Biogen and Alexion pharmaceuticals on US patent 5688688. The target products are AstraZeneca’s Synagisrespiratory treatment; Biogen’s Tysabri for multiple sclerosis; and Alexion’s Soliris, used to treat a life-threatening form of anemia

View complaint on prior smart Filed on Jan. 26, 2011; at District Court for the District of Delaware.

About Guna

Interested to learn things around me
This entry was posted in Patent case and tagged , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s